ライフサイエンスコーパス: anaplastic large-cell lymphoma

1 malignant cells of Hodgkin's lymphoma and by anaplastic large cell lymphoma.

2 ssed from lymphomatoid papulosis to systemic anaplastic large cell lymphoma.

3 ents for the treatment of advanced cutaneous anaplastic large cell lymphoma.

4 phase 2 trials in CD30+ Hodgkin lymphoma and anaplastic large cell lymphoma.

5 es, including classical Hodgkin lymphoma and anaplastic large cell lymphoma.

6 was observed in a patient with alk-positive anaplastic large-cell lymphoma.

7 th anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphoma.

8 target in patients with Hodgkin lymphoma and anaplastic large-cell lymphoma.

9 n children with refractory solid tumours and anaplastic large-cell lymphoma.

10 ne marrow and blood samples of patients with anaplastic large-cell lymphoma.

11 ic cancers, primarily Hodgkin's lymphoma and anaplastic large-cell lymphoma.

12 30-expressing Classical Hodgkin and systemic anaplastic large cell lymphomas.

13 n of tumors indistinguishable from patients' anaplastic large-cell lymphomas.

14 ophenotype characteristic of patient-derived anaplastic large-cell lymphomas.

15 Outcomes of 241 patients (112 anaplastic large-cell lymphoma, 102 peripheral T-cell ly

16 ma kinase (ALK)-positive and 48 ALK-negative anaplastic large cell lymphoma, 14 adult T-cell leukemia

17 Three patients had anaplastic large-cell lymphoma, 15 had mycosis fungoides

18 (lymphomatoid granulomatosis), 12/19 T-cell anaplastic large-cell lymphomas, 2/12 nodal peripheral T

19 In addition to 100% anaplastic large-cell lymphomas, 57% of other PTCL entit

20 One patient with cutaneous anaplastic large cell lymphoma (8 mg/kg) achieved a comp

21 All seven patients without anaplastic large-cell lymphoma achieved CR.

22 erfamily whose expression is up-regulated on anaplastic large cell lymphoma (ALCL) and Hodgkin lympho

23 leading to the neoplastic transformation of anaplastic large cell lymphoma (ALCL) and the Reed-Stern

24 vasion and contributes to the oncogenesis of anaplastic large cell lymphoma (ALCL) are not completely

25 We used various ALK-positive anaplastic large cell lymphoma (ALCL) cell lines to eval

26 normal and malignant lymphocytes, including anaplastic large cell lymphoma (ALCL) cells.

27 Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) constitutes an ide

28 The malignant cells in patients with anaplastic large cell lymphoma (ALCL) express CD30 and a

29 Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) frequently carries

30 onal antibodies in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL) has had profound c

31 A minority of LyP patients progress to anaplastic large cell lymphoma (ALCL) in which skin lesi

32 Anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALCL) is a CD30-positive

33 Anaplastic large cell lymphoma (ALCL) is a distinct clin

34 Anaplastic large cell lymphoma (ALCL) is a distinct enti

35 Anaplastic large cell lymphoma (ALCL) is a highly prolif

36 Anaplastic large cell lymphoma (ALCL) is a mature T-cell

37 Anaplastic large cell lymphoma (ALCL) is a peripheral T-

38 Systemic anaplastic large cell lymphoma (ALCL) is an aggressive C

39 Anaplastic large cell lymphoma (ALCL) is composed of lar

40 Anaplastic large cell lymphoma (ALCL) is the most common

41 In the DHL cell line, an Anaplastic Large Cell Lymphoma (ALCL) line, a DNA rearra

42 ntified in a subset of T-cell lymphomas with anaplastic large cell lymphoma (ALCL) morphology (ALK+ A

43 me clone was detected in LyP lesions and the anaplastic large cell lymphoma (ALCL) of 2 patients and

44 anaplastic lymphoma kinase-positive (ALK(+)) anaplastic large cell lymphoma (ALCL) patients.

45 In ALK-rearranged anaplastic large cell lymphoma (ALCL), a specific subtyp

46 with relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL), the single agent

47 model for the biology and treatment of CD30+ anaplastic large cell lymphoma (ALCL), we transplanted l

48 nase (NPM-ALK) are detected in 50% to 70% of anaplastic large cell lymphoma (ALCL), which is a T/null

49 nucleophosmin (NPM)-ALK fusion protein in an anaplastic large cell lymphoma (ALCL)-derived cell line

50 ne product expressed in a subset of cases of anaplastic large cell lymphoma (ALCL).

51 , which is expressed in a subset of systemic anaplastic large cell lymphoma (ALCL).

52 oma kinase (ALK) consistent with a null cell anaplastic large cell lymphoma (ALCL).

53 roliferation and malignant transformation of anaplastic large cell lymphoma (ALCL).

54 neoplastic cells of Hodgkin disease (HD) and anaplastic large cell lymphoma (ALCL).

55 s with relapsed or refractory (R/R) systemic anaplastic large cell lymphoma (ALCL).

56 nt of relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL).

57 were orally efficacious in animal models of anaplastic large cell lymphoma (ALCL).

58 in anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL).

59 gnancies, including Hodgkin disease (HD) and anaplastic large cell lymphoma (ALCL).

60 dominant genetic lesion underlying pediatric anaplastic large cell lymphomas (ALCL) and inflammatory

61 ) gene is characteristically translocated in Anaplastic Large Cell Lymphomas (ALCL) and the juxtaposi

62 The subset of CD30-positive anaplastic large cell lymphomas (ALCL) with the NPM-ALK

63 ung cancers (NSCLC) and approximately 70% of anaplastic large cell lymphomas (ALCL).

64 vely active nucleophosmin-ALK oncoprotein in anaplastic large cell lymphomas (ALCL).

65 us lymphoid-derived neoplasias, most notably anaplastic large-cell lymphoma (ALCL) and Hodgkin's lymp

66 arget for therapy of certain cancers such as anaplastic large-cell lymphoma (ALCL) and inflammatory m

67 defining events in several tumors, including anaplastic large-cell lymphoma (ALCL) and non-small cell

68 her variants) are expressed in many cases of anaplastic large-cell lymphoma (ALCL) but are absent fro

69 Most of the anaplastic large-cell lymphoma (ALCL) cases carry the t(

70 d neoplasms, was specifically found in all 4 anaplastic large-cell lymphoma (ALCL) cell lines, but no

71 Anaplastic large-cell lymphoma (ALCL) frequently carries

72 30% and 50% of patients with advanced-stage anaplastic large-cell lymphoma (ALCL) harbor the balance

73 ALK chimeric proteins in the pathogenesis of anaplastic large-cell lymphoma (ALCL) have been well def

74 Anaplastic large-cell lymphoma (ALCL) is a clinical and

75 Breast implant-associated anaplastic large-cell lymphoma (ALCL) is a recently desc

76 Systemic anaplastic large-cell lymphoma (ALCL) is a T-cell lympho

77 Systemic anaplastic large-cell lymphoma (ALCL) is an aggressive s

78 Primary CD30(Ki-1)-positive anaplastic large-cell lymphoma (ALCL) is considered by s

79 The non-Hodgkin lymphoma (NHL) subtype anaplastic large-cell lymphoma (ALCL) is frequently asso

80 blastoma protein (Rb) in the pathogenesis of anaplastic large-cell lymphoma (ALCL) is unknown.

81 ostic significance of survivin expression in anaplastic large-cell lymphoma (ALCL) is unknown.

82 LK) chimeric proteins in the pathogenesis of anaplastic large-cell lymphoma (ALCL) is well establishe

83 Anaplastic large-cell lymphoma (ALCL) of T- or null-cell

84 Anaplastic large-cell lymphoma (ALCL) provides an excell

85 Anaplastic large-cell lymphoma (ALCL) represents a heter

86 and is downregulated in T-lymphomas, such as anaplastic large-cell lymphoma (ALCL) tumors.

87 Anaplastic lymphoma kinase (ALK) -positive anaplastic large-cell lymphoma (ALCL) was excluded.

88 Anaplastic large-cell lymphoma (ALCL) was initially reco

89 anaplastic lymphoma kinase-positive (ALK(+)) anaplastic large-cell lymphoma (ALCL), and adult T-cell

90 -16 with Hodgkin's lymphoma (HL), three with anaplastic large-cell lymphoma (ALCL), and two with CD30

91 2;5)(p23;q35) translocation, associated with anaplastic large-cell lymphoma (ALCL), results in the pr

92 In anaplastic large-cell lymphoma (ALCL), the (2;5) chromos

93 t of patients with Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma (ALCL), the study by Jaco

94 plays an important pathogenetic role in ALK+ anaplastic large-cell lymphoma (ALCL).

95 -FLIP) may contribute to oncogenesis in ALK+ anaplastic large-cell lymphoma (ALCL).

96 mice most closely represent a model of human anaplastic large-cell lymphoma (ALCL).

97 of galectin-3 in all of the 8 cases of Ki-1+ anaplastic large-cell lymphoma (ALCL).

98 th anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphoma (ALCL).

99 a kinase (ALK) in patients with ALK-positive anaplastic large-cell lymphoma (ALCL).

100 type of human lymphoma (initially designated anaplastic large cell lymphoma [ALCL] or Ki-1/CD30-posit

101 oma [LBCL], 7 Burkitt's lymphoma [BL], and 4 anaplastic large cell lymphoma [ALCL]), and 25 nonmalign

102 gioimmunoblastic T-cell lymphoma [AITL], and anaplastic large-cell lymphoma [ALCL]) is difficult, wit

103 K+ xenografts in mice, including Karpas-299 (anaplastic large-cell lymphomas [ALCL]) and H3122 (NSCLC

104 Anaplastic large cell lymphomas (ALCLs) are caused by ch

105 The majority of pediatric anaplastic large cell lymphomas (ALCLs) carry the t(2;5)

106 Anaplastic Large Cell Lymphomas (ALCLs) carry translocat

107 AT3 activation in lymphomas, with a focus on anaplastic large cell lymphomas (ALCLs), which are known

108 ncluding anaplastic lymphoma kinase (ALK)(-) anaplastic large cell lymphomas (ALCLs).

109 ving ALK, occurring in approximately half of anaplastic large cell lymphomas (ALCLs).

110 oncogenic event in the pathogenesis of most anaplastic large cell lymphomas (ALCLs).

111 Anaplastic large-cell lymphomas (ALCLs) are a group of c

112 Primary cutaneous and primary nodal CD30+ anaplastic large-cell lymphomas (ALCLs) are distinct cli

113 Anaplastic large-cell lymphomas (ALCLs) bearing the t(2;

114 Anaplastic large-cell lymphomas (ALCLs) encompass at lea

115 hat drives the survival and proliferation of anaplastic large-cell lymphomas (ALCLs).

116 nd anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma (ALK-negative), despite t

117 Anaplastic lymphoma kinase-positive anaplastic large-cell lymphoma (ALK(+) ALCL) is a unique

118 t was associated with an improved outcome in anaplastic large-cell lymphoma, ALK positive.

119 In contrast, the malignant cells in anaplastic large cell lymphoma and most high-grade tumor

120 n partner of the ALK tyrosine kinase gene in anaplastic large-cell lymphoma and inflammatory myofibro

121 harbouring ALK translocations, particularly anaplastic large-cell lymphoma and inflammatory myofibro

122 e aberrantly expressed in a subset of T-cell anaplastic large-cell lymphoma and non-small-cell lung c

123 RC1; and expression of CD30 (the hallmark of anaplastic large-cell lymphoma) and of immunosuppressive

124 lymphomas (14 large-B-cell lymphomas and 10 anaplastic large-cell lymphomas), and 15 highly aggressi

125 g PTCL NOS, angioimmunoblastic, ALK-negative anaplastic large cell lymphoma, and enteropathy-associat

126 (SE, 4.4%), respectively, for patients with anaplastic large-cell lymphoma, and 63.8% (SE, 10.3%) an

127 of PTCL not otherwise specified (PTCL-NOS), anaplastic large-cell lymphoma, and adult T-cell leukemi

128 idging large-cell immunoblastic lymphoma and anaplastic large-cell lymphoma, and all 12 cases studied

129 phomas, diffuse large cell B-cell lymphomas, anaplastic large-cell lymphomas, and Epstein-Barr virus-

130 We also examine T-cell lymphomas, including anaplastic large-cell lymphoma, angioimmunoblastic T-cel

131 Rare histologies include Ki-1 anaplastic large cell lymphoma, angiotropic large cell l

132 plastic lymphoma kinase (NPM-ALK) expressing anaplastic large cell lymphoma are not completely unders

133 Hodgkin's lymphoma and anaplastic large-cell lymphoma are the two most common t

134 ocentric lymphomas of T or NK phenotype, and anaplastic large-cell lymphomas are cytotoxic T-or NK-ce

135 Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a rare periph

136 e treatment of relapsed Hodgkin and systemic anaplastic large cell lymphomas--both characterized by h

137 chromosome breaks and translocations in the anaplastic large cell lymphoma breakpoint regions of NPM

138 e treatment of relapsed Hodgkin lymphoma and anaplastic large-cell lymphoma by the Food and Drug Admi

139 MF), and three of 10 primary cutaneous CD30+ anaplastic large-cell lymphoma (C-ALCL).

140 In anaplastic large cell lymphoma, CD30 triggering induces

141 In contrast to Hodgkin lymphoma and systemic anaplastic large-cell lymphoma, CD30 expression of malig

142 ymphoma kinase (ALK)-positive and -negative, anaplastic large cell lymphoma cell lines and primary pa

143 optotic anaplastic lymphoma kinase-positive, anaplastic large cell lymphoma cell lines and that ectop

144 but not in NPM/ALK-negative, patient-derived anaplastic large cell lymphoma cell lines.

145 diffuse large B-cell lymphoma, ALK-positive anaplastic large cell lymphoma, chronic myelogenous leuk

146 d by the t(2;5) translocation in a subset of anaplastic large cell lymphomas, encodes a Mr 75,000 hyb

147 gene, formed by the t(2;5) translocation in anaplastic large-cell lymphoma, encodes a M(r) 75,000 hy

148 e peripheral T-cell lymphomas--including one anaplastic large cell lymphoma--expressed CD95.

149 a possible mechanism for escape of cutaneous anaplastic large cell lymphoma from tumor regression.

150 a (ENKCL), and ATLL and a lower incidence of anaplastic large-cell lymphoma; Hispanics had a higher i

151 for select patients, particularly those with anaplastic large-cell lymphoma histology.

152 lifications, or oncogenic mutations, such as anaplastic large-cell lymphoma, inflammatory myofibrobla

153 Breast implant-associated anaplastic large cell lymphoma is a rare cancer in patie

154 Anaplastic large-cell lymphoma is associated with a chro

155 In T-cell lymphomas, anaplastic large-cell lymphoma is defined by mutually ex

156 s highly expressed on Hodgkin's lymphoma and anaplastic large cell lymphoma, it is a promising target

157 n by small interfering RNA transfection of T-anaplastic large cell lymphoma Karpas 299.

158 More than 60% of anaplastic large-cell lymphomas (Ki-1 lymphoma) are asso

159 nerated to target different receptors on the anaplastic large cell lymphoma line L-82, but delivered

160 signature was robust enough to differentiate anaplastic large cell lymphoma (n = 32) from other PTCLs

161 7), adult T-cell lymphoma/leukemia (n = 4), anaplastic large-cell lymphoma (n = 2), and extranodal n

162 This subset included lines derived from anaplastic large cell lymphomas, non-small-cell lung can

163 found in lympho-hematopoietic malignancies, anaplastic large cell lymphoma (NPM-ALK) and acute promy

164 tivating ALK aberrations (eight of nine with anaplastic large-cell lymphoma, one of 11 with neuroblas

165 In SCID mouse xenograft models of anaplastic large cell lymphoma or Hodgkin disease, cAC10

166 al translocation detected in the majority of anaplastic large cell lymphoma patients, and has recentl

167 urable or evaluable solid or CNS tumours, or anaplastic large-cell lymphoma, refractory to therapy an

168 sed or refractory Hodgkin lymphoma, systemic anaplastic large cell lymphoma, relapsed or refractory B

169 , including rhabdomyosarcoma, neuroblastoma, anaplastic large cell lymphoma, renal cell carcinoma, an

170 ion and provided clues toward the outcome of anaplastic large cell lymphoma; the breakpoints of t(2;5

171 xcluding anaplastic lymphoma kinase-positive anaplastic large cell lymphoma), upfront auto-SCT was as

172 f lymphomatoid papulosis and cutaneous CD30+ anaplastic large cell lymphoma was shown, suggesting tha

173 rmed mycosis fungoides (T-MF), and cutaneous anaplastic large cell lymphoma were studied in parallel

174 cases of Th2-like PTCL studied, all cases of anaplastic large cell lymphoma, were immunoreactive for

175 itive mycosis fungoides or primary cutaneous anaplastic large-cell lymphoma who had been previously t

176 kinase (NPM-ALK) is a key oncogenic event in anaplastic large-cell lymphomas with the characteristic

177 oides, Sezary syndrome, or primary cutaneous anaplastic large cell lymphoma, with disease progression

178 o models of hematologic malignancies such as anaplastic large cell lymphoma, yet these mAb have not b